// MECHANISM_BIOLOGICAL_TARGET SYS_REF: GLP1R

GLP1R

ACTIVE_COMPETITORS 3 Assets
CLINICAL_EXPERIMENTS 11 Live Trials
BIOCLASS THERAPEUTIC_AREA

[01_MECHANISTIC_DESCRIPTIVE_NARRATIVE]

The glucagon-like peptide-1 receptor (GLP1R) is a G protein-coupled receptor (GPCR) found on beta cells of the pancreas and on neurons of the brain. It is involved in the control of blood sugar level by enhancing insulin secretion. In humans it is synthesised by the gene GLP1R, which is present on chromosome 6. It is a member of the glucagon receptor family of GPCRs. GLP1R is composed of two domains, one extracellular (ECD) that binds the C-terminal helix of GLP-1, and one transmembrane domain (TMD) that binds the N-terminal region of GLP-1. In the TMD domain a fulcrum of polar residues regulates the biased signaling of the receptor while the transmembrane helical boundaries and extracellular surface are a trigger for biased agonism.

[02_MACROMOLECULAR_3D_CONFORMATION]

Interactive structural projection resolved from the AlphaFold database engine configuration dataset mapping.

GLP1R
UNIPROT: P43220
ALPHAFOLD_3D_PREDICTION
INITIALIZING_STRUCTURAL_BIOMATRIX...

[03_ACTIVE_COMPETITIVE_LANDSCAPE]

[04_CROSS_REFERENCED_CLINICAL_EXPERIMENTS]

REGISTRY ID
EXPERIMENT TITLE
STAGE
EVALUATED ASSET
STATUS
RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
P-2
ALT-801
recruiting
Pemvidutide (ALT-801) DDI Study in Healthy Volunteers
P-1
ALT-801
completed
RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
P-2
ALT-801
active not recruiting
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
P-1
ALT-801
completed
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
P-1
ALT-801
completed
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
P-1
ALT-801
completed
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
P-2
ALT-801
completed
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
P-2
BMF-219
recruiting
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
P-2
BMF-219
recruiting
Food Effect Study in Healthy Volunteers
P-1
BMF-219
completed
Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants
P-1
BMF-650
active not recruiting